RUNX1 and prostate adenocarcinoma: To expand on this observation, we performed CRISPR-Cas9 mediated RUNX1-KO in another T-ALL cell line (Jurkat), AML (HL60) and prostate adenocarcinoma (DU145) cell lines, contexts where increased RUNX1 expression is associated with disease progression.30